-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
CAR-T therapy reaches historic milestone
Aug 08, 2017
The oncology world achieved an incredible gain last month, when the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of Novartis’ CTL019 (tisagenlecleucel), a groundbreaking chimeric antigen receptor T cell (CAR-T) therapy for the treatment of relapsed or refractory pediatric lymphoblastic leukemia (ALL).
This investigational therapy gained global attention in 2012 after successfully treating a pediatric ALL patient, seven-year-old Emily Whitehead, who had a resistant, life-threatening form of the disease. After facing two relapses and showing no response to chemo and radiation, Emily became the first pediatric patient to use the experimental therapy. Three weeks after receiving the treatment she was in remission and has been ever since.
The therapy involves removing T-cells from the patient and genetically engineering them to produce “Chimeric Antigen Receptors” on the surface of the T cells (“CAR-T cells”) that recognize a specific antigen on tumor cells and attack them. Once infused back into the patient’s body, the altered T cells actually multiply, travel all through the body, and will find and kill the cancer cells that harbor the antigen on their surfaces, and will remain in the patient ready to attack if the cancer returns. In this case the antigen is CD19, but in the future, many other antigens could be used to kill other kinds of cancer.
A new era for oncology
This is the first recommended approval for a CAR-T therapy, and it has enormous implications for oncology research. Unlike precision medicines, which are targeted therapies that attack very specific tumor mutations, CAR-T therapies could conceivably be engineered to address all types of cancers.
The recommended approval is likely to generate a flood of new CAR-T products, first in other leukemias and lymphomas, then targeting other tumor antigens, including BCMA (found on all Multiple Myeloma cancer cells), CD20, CD30, and others. Along with Novartis, Kite Pharma, Juno Therapeutics, and researchers at the First Affiliated Hospital of Zhejiang University in China, have also shown positive results in trials of CAR-T therapies, and many more are likely to follow. This first generation of CAR-T therapies have focused on hematologic or liquid tumors, which are more accessible, though over time researchers will likely find ways to engineer versions of CAR-T therapy that can attack solid tumors and other kinds of molecular target antigens.
These approvals will also likely begin to move up the sequence of treatment for certain cancers. Currently Novartis’ therapy is only approved as a last resort in the most desperately ill patients who have failed all other therapies. But as these therapies generate results, and physicians are better able to manage and minimize negative side effects, these or similar CAR-T products will be used earlier in the natural progression of the disease, and eventually may become a “first line” option for ALL, instead of chemotherapy or Bone Marrow Transplant, which is unpleasant, dangerous, and has long term complications.
There are still risks
However for CAR-T therapies to become a primary first line of defense for cancer patients, there are still obstacles to overcome, including rare, dangerous and sometimes fatal side effects. The most common serious side effect is cytokine-release syndrome (CRS), which leads to high fevers, joint pain, and a dramatic drop in blood pressure. In some cases, these side effects are mild enough to be managed, however about three-quarters of the patients who experience CRS require admission to an intensive care unit.
Researchers have found that treatments for inflammatory conditions like juvenile arthritis can ease the symptoms of CRS in response to CAR-T cell therapy, however these treatments are very expensive and thus only used reactively. Another solution could come from Bellicum Pharmaceuticals, which is exploring use of its Chemical Induction of Dimerization (CID) technology as a complimentary “safety-switch” to reduce the activity of the CAR-T cells, when needed to protect the patient.
The need for customization of each treatment also causes some industry leaders to argue that CAR-T therapy will be too expensive to use as a first line treatment. There are also concerns about the ability to safely handle the logistics of custom engineering each patients’ cells. But these are common problems that often arise with any groundbreaking therapy – or other innovations. Over time the ability to generate efficiencies in the engineering and logistics process will likely drive down costs while demonstrating the ability to safely manage and monitor patients’ cells throughout the treatment lifecycle.
These are obstacles that can be overcome. As newer and more complicated CAR-T products are designed and tested, these treatments will become safer and easier to manufacture and more effective over time.
We may still be years away from seeing CAR-T therapy as a first line of defense in all cancers, but this historic approval paves the way. This may be “the first” CAR-T to win FDA support but it will certainly not be the last.